- Home
- OTLK vs HDSN Comparison
OTLK vs HDSN Comparison
Compare OTLK & HDSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | HDSN |
|---|---|---|
| Founded | 2010 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 252.0M |
| IPO Year | 2016 | 1996 |
Fundamental Metrics
Financial Performance| Metric | OTLK | HDSN |
|---|---|---|
| Price | $1.41 | $6.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.50 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 11.8M | 577.5K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $8,146,123.00 | ★ $237,118,000.00 |
| Revenue This Year | $1,430.98 | $2.51 |
| Revenue Next Year | $173.23 | $2.38 |
| P/E Ratio | ★ N/A | $629.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $4.64 |
| 52 Week High | $3.39 | $10.52 |
Technical Indicators
Market Signals| Indicator | OTLK | HDSN |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 58.74 |
| Support Level | $1.21 | $5.55 |
| Resistance Level | $1.54 | $6.51 |
| Average True Range (ATR) | 0.18 | 0.28 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 17.54 | 70.39 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About HDSN Hudson Technologies Inc.
Hudson Technologies Inc is a refrigerant services company providing solutions to recurring challenges within the refrigeration industry. The company delivers environmentally sustainable offerings, covering the sale of refrigerant gases, recovery, reclamation, and reuse, as well as improving equipment performance through energy efficiency services, emergency air conditioning and refrigeration system repairs, refrigerant disposal, and carbon credit trading. It operates through one reportable segment. Its products and services are used in commercial air conditioning, industrial processing, and refrigeration systems, and include refrigerant and industrial gas sales, refrigerant management services (mainly reclamation of refrigerants), and RefrigerantSide services performed at customer sites.